Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine

Inclusion Criteria: * 15 to 70 years old * Migraine attacks according to the criteria proposed by the IHS * 3-12 Migraine attacks per month * adequate contraception * Willing and able to give written informed consent * Willing and able to complete the entire course of the study \& comply with instructions * Stable dose of preventive medication for at least 4 weeks Exclusion Criteria: * Disorders listen in groups 5-11 of the IHS Classification * Subject is pregnant or lactating. * Significant medical or psychiatric disease * Subject has a history of symptoms suggestive of ischemic heart disease (angina, myocardial infarction, documented silent ischemia) or other vascular disease, including Prinzmetal angina, claudication, Wolff-Parkinson-White syndrome, or other cardiac accessory conduction pathway arrhythmia * Subject has uncontrolled hypertension. * Subject has history of basilar, ophthalmoplegic, or hemiplegic migraine or serious neurologic condition associated with headache * Subject has used monoamine oxidase A inhibitors (MAOI-As) within 2 weeks of randomization * Subject has had serious adverse event while using another 5-HT agonist, or previous serious adverse event while using zolmitriptan or hypersensitivity to zolmitriptan or eletriptan * Using CYP3A4 inhibitors listed by the FDA as contraindicated with eletriptan * Moderate/severe hepatic/renal impairment * Subject currently using cimetidine * Concomitant medication treatment with a triptan, ergotamine or methysergide.